Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Transgenic Group Inc. (2342:JPX), powered by AI.
Transgenic Group Inc. is currently trading at ¥305. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Transgenic Group Inc. on Alpha Lenz.
Transgenic Group Inc.'s P/E ratio is -4.7.
“Transgenic Group Inc. trades at a P/E of -4.7 (undervalued) with modest ROE of -20.4%.”
Ask for details →Transgenic Group Inc. is a biotechnology company specializing in genetic engineering solutions across various sectors. The primary function of Transgenic Group Inc. is to develop and commercialize genetically modified organisms (GMOs) that enhance agricultural productivity, improve healthcare outcomes, and contribute to sustainable industrial processes. This company's operations significantly impact the agriculture industry by producing crop variants that exhibit increased resistance to pests and diseases and enhanced nutritional profiles. Additionally, in the healthcare sector, Transgenic Group Inc. focuses on advancements in gene therapy and personalized medicine by leveraging its expertise in genetic manipulation. The innovative technologies developed by the company have the potential to cater to increasing global demands in food security and precision medicine. Within the financial market, Transgenic Group Inc. represents a vital entity for investors interested in cutting-edge biotechnology and genetics-based solutions. Its contributions are essential for addressing global challenges related to food supply, health improvements, and environmental sustainability, making it a key player in advancing life sciences.
“Transgenic Group Inc. trades at a P/E of -4.7 (undervalued) with modest ROE of -20.4%.”
Ask for details →